SlideShare a Scribd company logo
1 of 15
Antiparkinsonism Agents
Dr. P.B. Mohite
Professor and Head
Department of Pharmaceutical Chemistry
M.E.S’s College of Pharmacy, Sonai
Parkinsonism
Parkinsonism, as a clinical entity, was first described by
James Parkinson in 1817.
It is a syndrome having the features of akinesia,
muscular rigidity, tremor, excessive salivation, seborrhoea,
mood changes (especially depression), and liver damage
that may be present in certain patients.
Normally the high concentrations of dopamine in basal
ganglia of the brain is reduced in the case of Parkinson’s
disease.
Parkinson’s disease is characterized by dopamine deficiency.
Definition
Parkinson's disease is degenerative disorder of the
CNS dopaminergic neurons which shows mainly motor
and sometimes cognition (thinking) related symptoms.
Movement-related (motor)
shaking, rigidity, slowness of movement and
difficulty with walking
Cognitive problems
Dementia
• Parkinson is caused due to imbalance of dopamine(DA) and
acetylcholine (Ach) .
• Ach and DA need to be balanced for smooth movement. DA
causes muscle relaxation while Ach causes contraction.
• Reduction of DA, in the basal ganglia results in imbalance of
those two and causes motor disorders.
• In some cases, at later stages of the disease reduction of Ach
which is also involved in learning and attention leads to dementia
Causes
The drugs used in the treatment of parkinsonism can be classified as
follows:
1. Drugs that increase brain levels of dopamine-Ex. Levodopa
2. DOPA decarboxylase inhibitors-ex. Carbidopa
3. Dopamine releasers- Ex. Amantidine
4. Anticholinergic agent- Ex. Trihexyphenydyl,
5. Phenothiazine anaologues- Ex. Ethopropazine
CLASSIFICATION
6. Miscellaneous drugs
• Antidepressants: Amitriptyline, trazadone
• α- tocopherol (vitamine E)
• Glutamate release inhibitor: Lamotrigine
• Glutamate receptor antagonist: Remacemide
• Glial-derived neurotrophic factor: GDNF
• Benztropine
• Orphenadrine citrate
• Chlorphenoxamine HCl
CLASSIFICATION
1. Drugs that increase brain levels of dopamine-Ex. Levodopa
Mechanism of action: External DA can’t cross BBB but the prodrug
L-dopa can. L-Dopa is dopamine with acid group to create an amino
acid functional group. The blood brain barrier has Amino Acid
Transporter which allows penetration of L-dopa, even though Ldopa
is less lipophillic than DA
• In the brain it gets metabolized into dopamine by the enzyme DOPA
decarboxylase.
• Thus, L-DOPA is used to increase dopamine concentrations in the
brain which is lowered in Parkinson
2. DOPA decarboxylase inhibitors-ex. Carbidopa
Mechanism of action:
It is a Dopamine decarboxylase inhibitors.
• It’s purpose is to increase efficacy of L-Dopa by preventing it’s
peripheral metabolic degradation and thus allowing more L-Dopa
to penetrate the brain
• While Dopamine decarboxylase exists both inside and outside the
brain, Carbidopa only blocks metabolism outside the brain cause it
can’t penetrate the brain.
Mechanism of action:
Amantadine appears to act by promoting presynaptic synthesis and
release of dopamine in the brain. It acts on glutamate receptors
through which dopaminergic system exerts the possible influence
on regulating the D1 and D2 receptors.
3. Dopamine releasers- Ex. Amantidine
4. Anticholinergic agents- Ex. Procyclidine, Trihexyphenidyl HCl
Trihexyphenidyl HCl Procyclidine HCl
Mechanism of action:
Anticholinergic medicines block cholinergic nerve impulses that
help control the muscles of the arms, legs and body by inhibiting
binding of acetylcholine with it’s receptors
•Anticholinergic medicines decrease levels of acetylcholine to
achieve a closer balance with dopamine levels.
5. Phenothiazine Derivatives: Ex.Ethopropazine
Mechanism of action:
These drugs act by reducing the unbalanced cholinergic activity in
the striatum of parkinsonian patients.
1. Antidepressants: Amitriptyline, trazadone
6. Miscellaneous drugs
2. Glutamate release inhibitor: Lamotrigine
3. Benztropine
•Orphenadrine citrate
6. Miscellaneous drugs
For any queries contact : mohitepb@gmail.com

More Related Content

What's hot

Antipsychotic Drugs/Medicinal Chemistry
Antipsychotic Drugs/Medicinal ChemistryAntipsychotic Drugs/Medicinal Chemistry
Antipsychotic Drugs/Medicinal ChemistryNarminHamaaminHussen
 
Synthesis Of Hetero-cyclic Drugs
Synthesis Of Hetero-cyclic DrugsSynthesis Of Hetero-cyclic Drugs
Synthesis Of Hetero-cyclic DrugsNirali Mistry
 
Reactions of heterocyclic chemistry
 Reactions of heterocyclic chemistry Reactions of heterocyclic chemistry
Reactions of heterocyclic chemistrysuraj wanjari
 
SYNTHETIC REAGENTS AND APPLICATION
SYNTHETIC REAGENTS AND APPLICATIONSYNTHETIC REAGENTS AND APPLICATION
SYNTHETIC REAGENTS AND APPLICATIONBinuja S.S
 
Structure Activity Relationships - Antipsychotics
Structure Activity Relationships - AntipsychoticsStructure Activity Relationships - Antipsychotics
Structure Activity Relationships - AntipsychoticsTulasi Raman
 
study of natural products as leads for new pharmaceuticals for the various cl...
study of natural products as leads for new pharmaceuticals for the various cl...study of natural products as leads for new pharmaceuticals for the various cl...
study of natural products as leads for new pharmaceuticals for the various cl...Subham Kumar Vishwakarma
 
Advanced Organic Chemistry - I
Advanced Organic Chemistry - IAdvanced Organic Chemistry - I
Advanced Organic Chemistry - IAjay Kumar
 
NEUROMUSCULAR BLOCKING DRUGS [CURARE ALKALOIDS]
NEUROMUSCULAR BLOCKING DRUGS [CURARE ALKALOIDS]NEUROMUSCULAR BLOCKING DRUGS [CURARE ALKALOIDS]
NEUROMUSCULAR BLOCKING DRUGS [CURARE ALKALOIDS]Shikha Popali
 
Antiparkinsonics Med chem lecture
Antiparkinsonics Med chem lecture Antiparkinsonics Med chem lecture
Antiparkinsonics Med chem lecture sagar joshi
 
Stereochemistry&drug action- mounika.perli
Stereochemistry&drug action- mounika.perliStereochemistry&drug action- mounika.perli
Stereochemistry&drug action- mounika.perlimounikaperli
 
Natural products as leads for new pharmaceuticals
Natural products as leads  for new pharmaceuticalsNatural products as leads  for new pharmaceuticals
Natural products as leads for new pharmaceuticalsShikha Popali
 
Neuromuscular blocking agents: Curare alkaloids
Neuromuscular blocking agents: Curare alkaloidsNeuromuscular blocking agents: Curare alkaloids
Neuromuscular blocking agents: Curare alkaloidsZainul Khan
 
Medicinal Chemistry of Antihypertensive agents pptx
Medicinal Chemistry of Antihypertensive agents pptxMedicinal Chemistry of Antihypertensive agents pptx
Medicinal Chemistry of Antihypertensive agents pptxSameena Ramzan
 
Morphine and its synthetic analoge
Morphine and its synthetic analogeMorphine and its synthetic analoge
Morphine and its synthetic analogeAfroj Shaikh
 
Structure activity relationship of Opiods
Structure activity relationship of OpiodsStructure activity relationship of Opiods
Structure activity relationship of OpiodsDr.Ameya Puranik
 
Antipsychotics Med chem lecture
Antipsychotics Med chem lecture Antipsychotics Med chem lecture
Antipsychotics Med chem lecture sagar joshi
 

What's hot (20)

Antipsychotic Drugs/Medicinal Chemistry
Antipsychotic Drugs/Medicinal ChemistryAntipsychotic Drugs/Medicinal Chemistry
Antipsychotic Drugs/Medicinal Chemistry
 
Synthesis Of Hetero-cyclic Drugs
Synthesis Of Hetero-cyclic DrugsSynthesis Of Hetero-cyclic Drugs
Synthesis Of Hetero-cyclic Drugs
 
Anti hypertensive drugs
Anti hypertensive drugsAnti hypertensive drugs
Anti hypertensive drugs
 
Reactions of heterocyclic chemistry
 Reactions of heterocyclic chemistry Reactions of heterocyclic chemistry
Reactions of heterocyclic chemistry
 
SYNTHETIC REAGENTS AND APPLICATION
SYNTHETIC REAGENTS AND APPLICATIONSYNTHETIC REAGENTS AND APPLICATION
SYNTHETIC REAGENTS AND APPLICATION
 
Structure Activity Relationships - Antipsychotics
Structure Activity Relationships - AntipsychoticsStructure Activity Relationships - Antipsychotics
Structure Activity Relationships - Antipsychotics
 
knorr pyrazole synthesis
knorr pyrazole synthesisknorr pyrazole synthesis
knorr pyrazole synthesis
 
study of natural products as leads for new pharmaceuticals for the various cl...
study of natural products as leads for new pharmaceuticals for the various cl...study of natural products as leads for new pharmaceuticals for the various cl...
study of natural products as leads for new pharmaceuticals for the various cl...
 
Advanced Organic Chemistry - I
Advanced Organic Chemistry - IAdvanced Organic Chemistry - I
Advanced Organic Chemistry - I
 
"Chemistry of Prostaglandins & Leukotrienes" , Tathagata Pradhan , Department...
"Chemistry of Prostaglandins & Leukotrienes" , Tathagata Pradhan , Department..."Chemistry of Prostaglandins & Leukotrienes" , Tathagata Pradhan , Department...
"Chemistry of Prostaglandins & Leukotrienes" , Tathagata Pradhan , Department...
 
Prodrug Design
Prodrug DesignProdrug Design
Prodrug Design
 
NEUROMUSCULAR BLOCKING DRUGS [CURARE ALKALOIDS]
NEUROMUSCULAR BLOCKING DRUGS [CURARE ALKALOIDS]NEUROMUSCULAR BLOCKING DRUGS [CURARE ALKALOIDS]
NEUROMUSCULAR BLOCKING DRUGS [CURARE ALKALOIDS]
 
Antiparkinsonics Med chem lecture
Antiparkinsonics Med chem lecture Antiparkinsonics Med chem lecture
Antiparkinsonics Med chem lecture
 
Stereochemistry&drug action- mounika.perli
Stereochemistry&drug action- mounika.perliStereochemistry&drug action- mounika.perli
Stereochemistry&drug action- mounika.perli
 
Natural products as leads for new pharmaceuticals
Natural products as leads  for new pharmaceuticalsNatural products as leads  for new pharmaceuticals
Natural products as leads for new pharmaceuticals
 
Neuromuscular blocking agents: Curare alkaloids
Neuromuscular blocking agents: Curare alkaloidsNeuromuscular blocking agents: Curare alkaloids
Neuromuscular blocking agents: Curare alkaloids
 
Medicinal Chemistry of Antihypertensive agents pptx
Medicinal Chemistry of Antihypertensive agents pptxMedicinal Chemistry of Antihypertensive agents pptx
Medicinal Chemistry of Antihypertensive agents pptx
 
Morphine and its synthetic analoge
Morphine and its synthetic analogeMorphine and its synthetic analoge
Morphine and its synthetic analoge
 
Structure activity relationship of Opiods
Structure activity relationship of OpiodsStructure activity relationship of Opiods
Structure activity relationship of Opiods
 
Antipsychotics Med chem lecture
Antipsychotics Med chem lecture Antipsychotics Med chem lecture
Antipsychotics Med chem lecture
 

Similar to Parkinsonism Agents Guide

Pharmacology of antiparkinsons drug
Pharmacology of antiparkinsons drugPharmacology of antiparkinsons drug
Pharmacology of antiparkinsons drugAshviniGovande
 
Antiparkinsonism agents
Antiparkinsonism agentsAntiparkinsonism agents
Antiparkinsonism agentsNisha Mhaske
 
Parkinsons_Disease_ M pharmacy Pharmacology.pptx
Parkinsons_Disease_ M pharmacy Pharmacology.pptxParkinsons_Disease_ M pharmacy Pharmacology.pptx
Parkinsons_Disease_ M pharmacy Pharmacology.pptxAyodhya Paradhe
 
Antiparkinson's Drugs
Antiparkinson's DrugsAntiparkinson's Drugs
Antiparkinson's DrugsBhudev Global
 
Treatment of Parkinsonism.pptx
Treatment of Parkinsonism.pptxTreatment of Parkinsonism.pptx
Treatment of Parkinsonism.pptxFarazaJaved
 
Parkinsons disease presentation
Parkinsons disease presentationParkinsons disease presentation
Parkinsons disease presentationsammyt1996
 
Carbidopa is given in combination L-dopa in Parkinsonian
 Carbidopa is given in combination L-dopa in Parkinsonian  Carbidopa is given in combination L-dopa in Parkinsonian
Carbidopa is given in combination L-dopa in Parkinsonian A M O L D E O R E
 
Anti -Parkinsonian Drugs-Medicinal Chemistry
Anti -Parkinsonian Drugs-Medicinal ChemistryAnti -Parkinsonian Drugs-Medicinal Chemistry
Anti -Parkinsonian Drugs-Medicinal ChemistryNarminHamaaminHussen
 
Presentation of Anti Parkinson drugs.
Presentation of Anti Parkinson drugs.Presentation of Anti Parkinson drugs.
Presentation of Anti Parkinson drugs.Rucha Tiwari
 
Antiparkinsonian drugs.pptx
Antiparkinsonian drugs.pptxAntiparkinsonian drugs.pptx
Antiparkinsonian drugs.pptxlakshmikakunuri1
 
Pharmacology - Parkinsonism
Pharmacology - ParkinsonismPharmacology - Parkinsonism
Pharmacology - ParkinsonismMBBS IMS MSU
 
Anti parkingsonian agents
Anti parkingsonian agents Anti parkingsonian agents
Anti parkingsonian agents Sujit Karpe
 
Dopamine & levodopa
Dopamine & levodopaDopamine & levodopa
Dopamine & levodopasom allul
 
Anti-Parkinsonism Drugs / Drugs Used in the treatment of Parkinson's Disease
Anti-Parkinsonism Drugs / Drugs Used in the treatment of Parkinson's DiseaseAnti-Parkinsonism Drugs / Drugs Used in the treatment of Parkinson's Disease
Anti-Parkinsonism Drugs / Drugs Used in the treatment of Parkinson's DiseaseKameshwaran Sugavanam
 

Similar to Parkinsonism Agents Guide (20)

Pharmacology of antiparkinsons drug
Pharmacology of antiparkinsons drugPharmacology of antiparkinsons drug
Pharmacology of antiparkinsons drug
 
Antiparkinsonism agents
Antiparkinsonism agentsAntiparkinsonism agents
Antiparkinsonism agents
 
Parkinsons_Disease_ M pharmacy Pharmacology.pptx
Parkinsons_Disease_ M pharmacy Pharmacology.pptxParkinsons_Disease_ M pharmacy Pharmacology.pptx
Parkinsons_Disease_ M pharmacy Pharmacology.pptx
 
Antiparkinson's Drugs
Antiparkinson's DrugsAntiparkinson's Drugs
Antiparkinson's Drugs
 
Parkinson
Parkinson Parkinson
Parkinson
 
Treatment of Parkinsonism.pptx
Treatment of Parkinsonism.pptxTreatment of Parkinsonism.pptx
Treatment of Parkinsonism.pptx
 
Drugs affecting the cns
Drugs affecting the cnsDrugs affecting the cns
Drugs affecting the cns
 
Parkinsons disease presentation
Parkinsons disease presentationParkinsons disease presentation
Parkinsons disease presentation
 
Carbidopa is given in combination L-dopa in Parkinsonian
 Carbidopa is given in combination L-dopa in Parkinsonian  Carbidopa is given in combination L-dopa in Parkinsonian
Carbidopa is given in combination L-dopa in Parkinsonian
 
Anti -Parkinsonian Drugs-Medicinal Chemistry
Anti -Parkinsonian Drugs-Medicinal ChemistryAnti -Parkinsonian Drugs-Medicinal Chemistry
Anti -Parkinsonian Drugs-Medicinal Chemistry
 
Presentation of Anti Parkinson drugs.
Presentation of Anti Parkinson drugs.Presentation of Anti Parkinson drugs.
Presentation of Anti Parkinson drugs.
 
Antiparkinsonian drugs.pptx
Antiparkinsonian drugs.pptxAntiparkinsonian drugs.pptx
Antiparkinsonian drugs.pptx
 
Pharmacology - Parkinsonism
Pharmacology - ParkinsonismPharmacology - Parkinsonism
Pharmacology - Parkinsonism
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Anti parkingsonian agents
Anti parkingsonian agents Anti parkingsonian agents
Anti parkingsonian agents
 
Dopamine
DopamineDopamine
Dopamine
 
Dopamine & levodopa
Dopamine & levodopaDopamine & levodopa
Dopamine & levodopa
 
Antiparkinsonian Drugs
Antiparkinsonian DrugsAntiparkinsonian Drugs
Antiparkinsonian Drugs
 
Anti-Parkinsonism Drugs / Drugs Used in the treatment of Parkinson's Disease
Anti-Parkinsonism Drugs / Drugs Used in the treatment of Parkinson's DiseaseAnti-Parkinsonism Drugs / Drugs Used in the treatment of Parkinson's Disease
Anti-Parkinsonism Drugs / Drugs Used in the treatment of Parkinson's Disease
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 

Recently uploaded

POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docxPoojaSen20
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionSafetyChain Software
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesFatimaKhan178732
 
Micromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersMicromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersChitralekhaTherkar
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
 
MENTAL STATUS EXAMINATION format.docx
MENTAL     STATUS EXAMINATION format.docxMENTAL     STATUS EXAMINATION format.docx
MENTAL STATUS EXAMINATION format.docxPoojaSen20
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991RKavithamani
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting DataJhengPantaleon
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 

Recently uploaded (20)

POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
Staff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSDStaff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSD
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docx
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory Inspection
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application )
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and Actinides
 
Micromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersMicromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of Powders
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
MENTAL STATUS EXAMINATION format.docx
MENTAL     STATUS EXAMINATION format.docxMENTAL     STATUS EXAMINATION format.docx
MENTAL STATUS EXAMINATION format.docx
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 

Parkinsonism Agents Guide

  • 1. Antiparkinsonism Agents Dr. P.B. Mohite Professor and Head Department of Pharmaceutical Chemistry M.E.S’s College of Pharmacy, Sonai
  • 2. Parkinsonism Parkinsonism, as a clinical entity, was first described by James Parkinson in 1817. It is a syndrome having the features of akinesia, muscular rigidity, tremor, excessive salivation, seborrhoea, mood changes (especially depression), and liver damage that may be present in certain patients. Normally the high concentrations of dopamine in basal ganglia of the brain is reduced in the case of Parkinson’s disease. Parkinson’s disease is characterized by dopamine deficiency.
  • 3. Definition Parkinson's disease is degenerative disorder of the CNS dopaminergic neurons which shows mainly motor and sometimes cognition (thinking) related symptoms. Movement-related (motor) shaking, rigidity, slowness of movement and difficulty with walking Cognitive problems Dementia
  • 4.
  • 5. • Parkinson is caused due to imbalance of dopamine(DA) and acetylcholine (Ach) . • Ach and DA need to be balanced for smooth movement. DA causes muscle relaxation while Ach causes contraction. • Reduction of DA, in the basal ganglia results in imbalance of those two and causes motor disorders. • In some cases, at later stages of the disease reduction of Ach which is also involved in learning and attention leads to dementia Causes
  • 6. The drugs used in the treatment of parkinsonism can be classified as follows: 1. Drugs that increase brain levels of dopamine-Ex. Levodopa 2. DOPA decarboxylase inhibitors-ex. Carbidopa 3. Dopamine releasers- Ex. Amantidine 4. Anticholinergic agent- Ex. Trihexyphenydyl, 5. Phenothiazine anaologues- Ex. Ethopropazine CLASSIFICATION
  • 7. 6. Miscellaneous drugs • Antidepressants: Amitriptyline, trazadone • α- tocopherol (vitamine E) • Glutamate release inhibitor: Lamotrigine • Glutamate receptor antagonist: Remacemide • Glial-derived neurotrophic factor: GDNF • Benztropine • Orphenadrine citrate • Chlorphenoxamine HCl CLASSIFICATION
  • 8. 1. Drugs that increase brain levels of dopamine-Ex. Levodopa Mechanism of action: External DA can’t cross BBB but the prodrug L-dopa can. L-Dopa is dopamine with acid group to create an amino acid functional group. The blood brain barrier has Amino Acid Transporter which allows penetration of L-dopa, even though Ldopa is less lipophillic than DA • In the brain it gets metabolized into dopamine by the enzyme DOPA decarboxylase. • Thus, L-DOPA is used to increase dopamine concentrations in the brain which is lowered in Parkinson
  • 9. 2. DOPA decarboxylase inhibitors-ex. Carbidopa Mechanism of action: It is a Dopamine decarboxylase inhibitors. • It’s purpose is to increase efficacy of L-Dopa by preventing it’s peripheral metabolic degradation and thus allowing more L-Dopa to penetrate the brain • While Dopamine decarboxylase exists both inside and outside the brain, Carbidopa only blocks metabolism outside the brain cause it can’t penetrate the brain.
  • 10. Mechanism of action: Amantadine appears to act by promoting presynaptic synthesis and release of dopamine in the brain. It acts on glutamate receptors through which dopaminergic system exerts the possible influence on regulating the D1 and D2 receptors. 3. Dopamine releasers- Ex. Amantidine
  • 11. 4. Anticholinergic agents- Ex. Procyclidine, Trihexyphenidyl HCl Trihexyphenidyl HCl Procyclidine HCl Mechanism of action: Anticholinergic medicines block cholinergic nerve impulses that help control the muscles of the arms, legs and body by inhibiting binding of acetylcholine with it’s receptors •Anticholinergic medicines decrease levels of acetylcholine to achieve a closer balance with dopamine levels.
  • 12. 5. Phenothiazine Derivatives: Ex.Ethopropazine Mechanism of action: These drugs act by reducing the unbalanced cholinergic activity in the striatum of parkinsonian patients.
  • 13. 1. Antidepressants: Amitriptyline, trazadone 6. Miscellaneous drugs
  • 14. 2. Glutamate release inhibitor: Lamotrigine 3. Benztropine •Orphenadrine citrate 6. Miscellaneous drugs
  • 15. For any queries contact : mohitepb@gmail.com